Article Text

Download PDFPDF

AB0316 Hospital admissions of patients with rheumatoid arthritis treated with dmard
  1. EC Cervantes Pérez,
  2. JR Maneiro,
  3. A Souto Vilas,
  4. JA Mera Varela,
  5. JJ Gόmez-Reino
  1. Ramόn Domínguez Foundation, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain


Objectives To describe hospital admissions and contributing factors in patients with rheumatoid arthritis (RA) treated biological DMARD (b-DMAR) and conventional synthetic DMARD (cs-DMAR).

Methods Retrospective observational study of RA patients admitted to the hospital for any cause from 2010 to 2015. Demographic, clinical and therapeutic characteristics were collected from the medical charts. Multivariate and univariate models were used to identify variables associated with admissions for any cause, major adverse cardiovascular events (MACE), and infection. The statistical program Stata 14.0 was used for the analysis.

Results In the period 2010–2015, 26% of all RA patients were treated with b-DMARD. There were a total of 1251 hospital admissions for any cause in 600 patients; 1055 admissions in 477 patients treated with cs-DMAR and 196 admissions in 123 patients treated with b-DMAR. Of the 1251 admissions, 251 were due to infections and 60 to MACE. Demographic characteristics, comorbidities and treatment are disclosed in table. In the multivariate analysis, diabetes mellitus (p<0.001), and hypertension (p=0.029) were associated with admission for infections, and hypertension (p 0.011), and dyslipidemia (p=0.02) with admissions for MACE.

Conclusions infections and MACE are a significant cause of hospital admission in patients with rheumatoid arthritis. Comorbidities as diabetes, hypertension and dyslipidemia but not b-DMARD are significantly associated with admission for infection or MACE.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.